Helicobacter Pylori Infections - Market Insight, Epidemiology and Market Forecast - 2027

Helicobacter Pylori Infections - Market Insight, Epidemiology and Market Forecast - 2027

  • Pages: 120
  • Geography: Global
  • Delivery Timeline: 5 Business Days
  • Publication: Aug, 2018
  • SKU: DIMI0095
  • Single User License
    (20% Off)
    $6,250.00
    $5000
  • Site License
    (30% Off)
    $12,500.00
    $8750
  • Global License
    (40% Off)
    $18,750.00
    $11250
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight’s ‘Helicobacter Pylori Infections  - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Helicobacter Pylori Infections in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. 
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Helicobacter Pylori Infections from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2016-2027
Helicobacter Pylori Infectious - Disease Understanding and Treatment Algorithm
Helicobacter pylori (H. pylori) is an infection caused by bacteria which causes infection in the stomach. This infections causes changes to the stomach and duodenum which lead to gastritis and stomach cancer. H. pylori is spread by consuming food or water contaminated with fecal matter.
The DelveInsight Helicobacter Pylori Infections market report gives the thorough understanding of the Helicobacter Pylori Infections by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Helicobacter Pylori Infections in the US, Europe, and Japan.

Helicobacter Pylori Infections Epidemiology
The Helicobacter Pylori Infections epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Prevalence of Helicobacter Pylori Infections, Prevalence by types of Helicobacter Pylori Infections, Age Specific Prevalence of Helicobacter Pylori Infections and others] scenario of Helicobacter Pylori Infections in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
In the United States and other developed countries, infection with H. pylori is unusual during childhood but becomes more common during adulthood. However, in developing countries, most children are infected with H. pylori before age 10. Male are predominantly more prevalent to H.Pylori infection then female.

According to a research by CDC, helicobacter pylori causes more than 90% of duodenal ulcers and up to 80% of gastric ulcers.

Helicobacter Pylori Infections Drug Chapters
This segment of the Helicobacter Pylori Infections report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The current therapeutic market for the treatment of Helicobacter Pylori Infections is dependent on Proton Pump Inhibitors and Potassium-competitive acid blockers. Since, gastric ulcer, duodenal ulcer and recurrence of infections cause severe morbidity, most of the marketed drugs are approved to treat these manifestations. Aciphex (Eisai Pharmaceuticals), Nexium (AstraZeneca), Prilosec (Astrazeneca) and Takecab (Takeda) are drug used for the treatment of patients with risk reduction of NSAID-associated gastric ulcer, duodenal ulcer, Gastric ulcer, duodenal ulcer recurrence, gastroesophageal reflux disease.

Helicobacter Pylori Infections Market Outlook
The Helicobacter Pylori Infections market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 
Expected launch of emerging therapies such as TAK - 438 (Takeda), RHB - 105 (Redchill Biopharma), Tegoprazan (RaQualia), and other therapies are expected to impact the market size of Helicobacter Pylori Infections in upcoming years.

Helicobacter Pylori Infections Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Helicobacter Pylori Infections Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Helicobacter Pylori Infections Report Key Strengths

• 10 Years Forecast

• 7MM Coverage 

• Epidemiology Segmentation

• Sub-type Segmentation

• Key Cross Competition 

• Highly Analyzed Market

• Drugs Uptake

Helicobacter Pylori Infections Report Assessment

• Current Treatment Practices

• Unmet Needs

• Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Helicobacter Pylori Infections market

• Organize sales and marketing efforts by identifying the best opportunities for Helicobacter Pylori Infections market

• To understand the future market competition in the Helicobacter Pylori Infections market.

1. Report Introduction
2. Helicobacter Pylori Infections  Market Overview at a Glance
2.1. 7 Major Market Size (%) of Helicobacter Pylori Infections  in 2017
2.2. 7 Major Market Size (%) of Helicobacter Pylori Infections  in 2027
3. Disease Background and Overview: Helicobacter Pylori Infections
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. 7MM Prevalent Cases of Helicobacter Pylori Infections  (2016-2027)
4.2. 7MM Age-Specific Prevalent Cases of Helicobacter Pylori Infections (2016-2027)
4.3. 7MM Type Specific Prevalent Cases of Helicobacter Pylori Infections (2016-2027)
5. Helicobacter Pylori Infections : Country- Wise Epidemiology
5.1. United States
5.1.1. Prevalent Cases of Helicobacter Pylori Infections  (2016-2027)
5.1.2. Age Specific Prevalent Cases of Helicobacter Pylori Infections (2016-2027)
5.1.3. Type Specific Prevalent Cases of Helicobacter Pylori Infections (2016-2027)
5.2. EU-5
5.2.1. Assumptions and Rationale
5.3. Germany
5.3.1. Prevalent Cases of Helicobacter Pylori Infections  (2016-2027)
5.3.2. Age Specific Prevalent Cases of Helicobacter Pylori Infections (2016-2027)
5.3.3. Type Specific Prevalent Cases of Helicobacter Pylori Infections (2016-2027)
5.4. France
5.4.1. Prevalent Cases of Helicobacter Pylori Infections  (2016-2027)
5.4.2. Age Specific Prevalent Cases of Helicobacter Pylori Infections (2016-2027)
5.4.3. Type Specific Prevalent Cases of Helicobacter Pylori Infections (2016-2027)
5.5. Italy
5.5.1. Prevalent Cases of Helicobacter Pylori Infections  (2016-2027)
5.5.2. Age Specific Prevalent Cases of Helicobacter Pylori Infections (2016-2027)
5.5.3. Type Specific Prevalent Cases of Helicobacter Pylori Infections (2016-2027)
5.6. Spain
5.6.1. Prevalent Cases of Helicobacter Pylori Infections  (2016-2027)
5.6.2. Age Specific Prevalent Cases of Helicobacter Pylori Infections (2016-2027)
5.6.3. Type Specific Prevalent Cases of Helicobacter Pylori Infections (2016-2027)
5.7. United Kingdom
5.7.1. Prevalent Cases of Helicobacter Pylori Infections  (2016-2027)
5.7.2. Age Specific Prevalent Cases of Helicobacter Pylori Infections (2016-2027)
5.7.3. Type Specific Prevalent Cases of Helicobacter Pylori Infections (2016-2027)
5.8. Japan
5.8.1. Prevalent Cases of Helicobacter Pylori Infections  (2016-2027)
5.8.2. Age Specific Prevalent Cases of Helicobacter Pylori Infections (2016-2027)
5.8.3. Type Specific Prevalent Cases of Helicobacter Pylori Infections (2016-2027)
6. Treatments & Medical Practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Marketed Products
7.1. NEXIUM: AstraZeneca
7.1.1. Drug Description
7.1.2. Mechanism of Action
7.1.3. Regulatory Milestones
7.1.4. Advantages and Disadvantages
7.1.5. Safety and Efficacy
7.1.6. Product Profile
7.2. ACIPHEX: Eisai Pharmaceuticals
7.2.1. Drug Description
7.2.2. Mechanism of Action
7.2.3. Regulatory Milestones
7.2.4. Advantages and Disadvantages
7.2.5. Safety and Efficacy
7.2.6. Product Profile
7.3. Prilosec: Astrazeneca
7.3.1. Drug Description
7.3.2. Mechanism of Action
7.3.3. Regulatory Milestones
7.3.4. Advantages and Disadvantages
7.3.5. Safety and Efficacy
7.3.6. Product Profile
7.4. Takecab: Takeda
7.4.1. Drug Description
7.4.2. Mechanism of Action
7.4.3. Regulatory Milestones
7.4.4. Advantages and Disadvantages
7.4.5. Safety and Efficacy
7.4.6. Product Profile
List to be continued in the report…
8. Emerging Therapies
8.1. Key Cross Competition
8.2. RHB - 105: RedHill Biopharma
8.2.1. Regulatory Milestones
8.2.2. Clinical Development
8.2.3. Product Profile
8.2.4. Clinical Pipeline Activity
8.2.5. Ongoing Trials Information
8.2.6. Clinical Trial by Phase
8.3. Tegoprazan: RaQualia
8.3.1. Regulatory Milestones
8.3.2. Clinical Development
8.3.3. Product Profile
8.3.4. Clinical Pipeline Activity
8.3.5. Ongoing Trials Information
8.3.6. Clinical Trial by Phase
8.4. TAK - 438: Takeda
8.4.1. Regulatory Milestones
8.4.2. Clinical Development
8.4.3. Product Profile
8.4.4. Clinical Pipeline Activity
8.4.5. Ongoing Trials Information
8.4.6. Clinical Trial by Phase
List to be continued in the report…
9. Helicobacter Pylori Infections  Market Size
9.1. Key Findings
9.2. Total 7MM Helicobacter Pylori Infections Market Analysis
9.3. Overview of Total Helicobacter Pylori Infections  Market
9.4. Market size of Helicobacter Pylori Infections  Market by 7MM (2016-2027)
10. 7MM: Country-Wise Market Analysis
10.1. United States Market Size
10.1.1. Total Market Size of Helicobacter Pylori Infections
10.1.2. Market Size of Helicobacter Pylori Infections  by Therapies
10.2. Germany Market Size
10.2.1. Total Market Size of Helicobacter Pylori Infections
10.2.2. Market Size of Helicobacter Pylori Infections  by Therapies
10.3. France Market Size
10.3.1. Total Market Size of Helicobacter Pylori Infections
10.3.2. Market Size of Helicobacter Pylori Infections  by Therapies
10.4. Italy Market Size
10.4.1. Total Market Size of Helicobacter Pylori Infections
10.4.2. Market Size of Helicobacter Pylori Infections  by Therapies
10.5. Spain Market Size
10.5.1. Total Market Size of Helicobacter Pylori Infections
10.5.2. Market Size of Helicobacter Pylori Infections  by Therapies
10.6. United Kingdom Market Size
10.6.1. Total Market Size of Helicobacter Pylori Infections
10.6.2. Market Size of Helicobacter Pylori Infections  by Therapies
10.7. Japan Market Size
10.7.1. Total Market Size of Helicobacter Pylori Infections
10.7.2. Market Size of Helicobacter Pylori Infections  by Therapies
11. Market Drivers
12. Market Barriers
13. Report Methodology
13.1. Sources Used
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Table 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Table 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Table 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Table 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Table 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Table 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Table 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Table 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Table 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Table 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Table 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Table 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Table 26 RHB - 105, Clinical Trials by Zone, 2018
Table 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Table 28 Tegoprazan , Clinical Trials by Zone, 2018
Table 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Table 30 TAK - 438, Clinical Trials by Zone, 2018
Table 31 Total 7 Major Market Size in USD, Million (2016-2027)
Table 32 Region wise Market Size) in USD, Million (2016-2027)
Table 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 34 United States Market Size in USD, Million (2016-2027)
Table 35 United States Market Size by Therapy in USD, Million (2016-2027)
Table 36 Germany  Market Size in USD, Million (2016-2027)
Table 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 38 France  Market Size in USD, Million (2016-2027)
Table 39 France Market Size by Therapy in USD, Million (2016-2027)
Table 40 Italy  Market Size in USD, Million (2016-2027)
Table 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 42 Spain Market Size in USD, Million (2016-2027)
Table 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 44 United Kingdom Market Size in USD, Million (2016-2027)
Table 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 46 Japan Market Size in USD, Million (2016-2027)
Table 47 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Helicobacter Pylori Infections  in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 3 Type specific prevalent cases of Helicobacter Pylori Infections in 7MM (2016-2027)
Figure 4 Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 5 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 6 Type specific prevalent cases of Helicobacter Pylori Infections in the US (2016-2027)
Figure 7 Prevalent Cases of Helicobacter Pylori Infections in the Germany (2016-2027)
Figure 8 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 9 Type specific prevalent cases of Helicobacter Pylori Infections in Germany (2016-2027)
Figure 10 Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 11 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 12 Type specific prevalent cases of Helicobacter Pylori Infections in Italy (2016-2027)
Figure 13 Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 14 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 15 Type specific prevalent cases of Helicobacter Pylori Infections in Spain (2016-2027)
Figure 16 Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 17 Age Specific Prevalent Cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 18 Type specific prevalent cases of Helicobacter Pylori Infections in France (2016-2027)
Figure 19 Prevalent Cases of Helicobacter Pylori Infections  in the UK (2016-2027)
Figure 20 Age Specific Prevalent Cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 21 Type specific prevalent cases of Helicobacter Pylori Infections in the UK (2016-2027)
Figure 22 Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 23 Age Specific Prevalent Cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 24 Type specific prevalent cases of Helicobacter Pylori Infections in Japan (2016-2027)
Figure 25 RHB - 105, Clinical Trials by Recruitment status, 2018
Figure 26 RHB - 105, Clinical Trials by Zone, 2018
Figure 27 Tegoprazan, Clinical Trials by Recruitment status, 2018
Figure 28 Tegoprazan , Clinical Trials by Zone, 2018
Figure 29 TAK - 438, Clinical Trials by Recruitment status, 2018
Figure 30 TAK - 438, Clinical Trials by Zone, 2018
Figure 31 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 32 Region wise Market Size) in USD, Million (2016-2027)
Figure 33 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United States Market Size in USD, Million (2016-2027)
Figure 35 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Germany  Market Size in USD, Million (2016-2027)
Figure 37 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 38 France  Market Size in USD, Million (2016-2027)
Figure 39 France Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Italy  Market Size in USD, Million (2016-2027)
Figure 41 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Spain Market Size in USD, Million (2016-2027)
Figure 43 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 44 United Kingdom Market Size in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 46 Japan Market Size in USD, Million (2016-2027)
Figure 47 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 48 Market Drivers
Figure 49 Market Barriers

 

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.